UK's Oxford Biomedica maintains annual outlook
28/07/2025 07:56
July 28 (Reuters) - Britain's Oxford Biomedica OXB.L on Monday maintained its annual forecasts for revenue and profit after it said first-half sales are expected to jump around 40% as orders remain strong for the cell and gene therapy developer and manufacturer. (Reporting by Ankita Bora in Bengaluru) ((Ankita.Bora@thomsonreuters.com;))